Wednesday, December 15, 2010
Search of: ovarian cancer | Open Studies | Adult | received from 10/01/2010 to 12/15/2010 - List Results - ClinicalTrials.gov
Search of: ovarian cancer | Open Studies | Adult | received from 10/01/2010 to 12/15/2010 - List Results (34) - ClinicalTrials.gov
HealthLinx reports solid data from OvPlex study - ovarian cancer, medical diagnostics - Australian Life Scientist
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment (IL-12)
"EGEN, Inc. announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions. The University of Alabama at Birmingham (UAB) Hospital is the first member institution to open enrollment. Dr. Ronald Alvarez, of UAB Hospital, is the Study Chair for the trial. The GOG Principal Investigator at UAB Hospital is Dr. Mack Barnes....The product utilizes the Company's proprietary TheraPlas® delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply. We expect a number of the leading cancer centers in the U.S. to participate in this study and planning is underway to initiate additional Phase II trials in 2011, including the evaluation of EGEN-001 in treatment of colorectal cancer patients."...cont'd
Blogger's Note: a similar issue was reported and largely ignored regarding colorectal cancer
“The data were absolutely missed. They weren’t emphasized, and they weren’t brought to the attention of oncologists,”...
NCI Cancer Bulletin: Statistical Strength in Numbers: International Clinical Trials for Rare Cancers
“International trials for rare cancers offer many advantages over separate trials done in different countries or regions,” explained Dr. Jack Welch of the Clinical Investigations Branch in NCI’s Cancer Therapy Evaluation Program (CTEP). “By bringing patients together, international trials can accrue faster, and they offer lower collective administrative costs, shared infrastructure, centralized resources, and use of existing networks.”.....On December 10, NCI and the American Society of Clinical Oncology (ASCO) convened a meeting of international stakeholders to explore ways to collaborate across borders on clinical trials for rare cancers. Nearly 100 representatives from 75 institutions participated in the day-long meeting, which was supported by CTEP, NIH’s Office of Rare Diseases Research (ORDR), NCI’s Office of Advocacy Relations (OAR), and ASCO. In addition to representatives from NIH, the FDA, the HHS Office for Human Research Protections, and NCI’s Clinical Trials Cooperative Group Program, attendees included investigators from Canada, France, Italy, Japan, Korea, the United Kingdom, the European Organisation for Research and Treatment of Cancer, and representatives of patient advocacy organizations and the pharmaceutical industry....cont'd
Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines — JCO
Conclusion: Recommendations issued in the NCCN guidelines are largely developed from lower levels of evidence but with uniform expert opinion. This underscores the urgent need and available opportunities to expand evidence base in oncology.
Components of family history associated with women's disease perceptions for cancer: A report from the Family Healthware™ Impact Trial - abstract
PURPOSE: To determine the specific components of family history and personal characteristics related to disease perceptions about breast, colon, and ovarian cancers.
RECENT FINDINGS: 'Triple negative' phenotype is traditionally referred to as a specific subtype of breast cancer negative for estrogen receptor, progesterone receptor and HER2 expression. Recent studies have shown that such 'triple negative' phenotype also exists in ovarian and endometrial cancer. TNEOC accounts for about 15% of epithelial ovarian carcinoma. This specific subtype tends to exhibit more aggressive characteristics and a worse prognosis. The molecular features of TNEOC are similar to those of 'triple negative' breast cancer (TNBC), a widely studied histological subtype. Recently, a panel of specific pathologic biomarkers has been identified in TNBC. Currently, phase I and phase II trials to examine the safety and efficacy of a poly (ADP-ribose) polymerase inhibitor (olaparib) and angiogenesis inhibitors (sunitinib and bevacizumab) in TNBC are ongoing. These TNBC-associated pathologic markers could be used to screen for novel prognostic factors and therapeutic targets in TNEOC.
SUMMARY: 'Triple negative' phenotype has important implications for clinical management of patients with ovarian cancer.
AbstractThe majority of patients with stage III/IV ovarian carcinoma that respond initially to standard therapies ultimately undergo relapse due to the survival of small populations of cells with tumor-initiating potential. These ovarian cancer-initiating cells (OCIC) are sometimes called cancer stem cells (CSC) since they express stem cell markers, and can survive conventional therapies such as chemotherapy, which usually target rapidly replicating tumor cells, and give rise to recurrent tumors that are more chemo-resistant and more aggressive. Thus it would be desirable to develop a therapy that could selectively target OCIC and be used to complement the conventional therapies. In the present study, we isolated a subset of ovarian cancer cells with a CD44(+) phenotype in samples from patients with ovarian cancer that possess CSC properties including the formation of spheroids in culture, self-renewal and the ability to be engrafted in immune-compromised mice. We next explored the use of immunotherapy using fusions of dendritic cells (DC) and OCIC to specifically target the OCIC sub-populations. Fusion cells prepared in this way activated T cells to express elevated levels of IFN-γ with enhanced killing of CD44(+) ovarian cancer cells. We envision a combined approach where conventional therapies such as chemotherapy kill the bulk of tumor cells, whereas OCIC-reactive CTL target the resistant OCIC fraction. A combined therapy such as this may represent a promising approach for the treatment of ovarian cancer.
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
AbstractBACKGROUND: Pathologic and genetic data suggest that epithelial ovarian cancer may consist of indolent and aggressive phenotypes. The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies.
CONCLUSIONS: The current analysis suggested that reductions in ovarian cancer mortality using available screening technologies on an annual basis are likely to be modest. A model that incorporated 2 clinical phenotypes of ovarian carcinoma into its natural history predicted an even smaller potential reduction in mortality because of the more frequent diagnosis of indolent cancers at early stages.
abstract: Aspiration cytology of ovarian cystic masses: histologic correlation and review of the literature.
Objective: To determine the diagnostic accuracy of cytologic evaluation of ovarian cystic masses.
Study Design: Sixty-seven ovarian cystic masses with fine needle aspiration cytology and concurrent or subsequent cystectomy/oophorectomy with histology were examined. Correlations with malignancy were made with 4 parameters: serum CA-125, radiographic size and architecture, and cytology.
Sunday, December 12, 2010
Uterine cancer screening effective, but not yet recommended – The Chart - CNN.com Blogs (Lynch Syndrome)
"..However Smith notes many postmenopausal women receive a late diagnosis because they overlook a very important warning sign. "The American Cancer Society places a great deal of emphasis of being aware that postmenopausal bleeding is not normal and if it occurs, contact a doctor immediately," he advises."
Tuesday, December 07, 2010
Monday, December 06, 2010
The Dollar Cost of Medicare
|Appeared in the New Brunswick Telegraph Journal|
|Release Date:||November 16, 2010|
The true cost of Medicare for individuals and families in Canada is often misunderstood, with many people thinking it’s either free or covered by our provincial health insurance premiums....cont\d
Sunday, December 05, 2010
Friday, December 03, 2010
Women's Health -Summary: Ovarian stimulation: is there a long-term risk for ovarian, breast and endometrial cancer?
Wednesday, December 01, 2010
SUMMARY: A “champion” is a “charismatic advocate of a belief, practice,
program, policy and/or technology.”1 It is a champion’s unique combination
of skills—passion, persistence, and persuasiveness—that distinguish him
or her from other advocates. A 2007 Cochrane review concluded that the
use of opinion leaders can successfully promote evidence-based practices.2
Engaging influential opinion leaders can be an effective advocacy approach
for advancing social, economic, political, or public health issues.
This is our 4th Annual Evidence-based Complementary & Alternative Cancer Therapies conference, aka CAM for Cancer. Crowne Plaza Hotel, West Palm Beach, FL REGISTRATION IS OPEN until FEBRUARY 20 (because we have to have a count to order the ORGANIC food). Conference cost:$159 (includes 5 organic meals and 4 organic snacks)
HOTEL Rate is $120 per night and will hold for several days in advance and afterwards.
RESERVE a HOTEL Room Opens to a new page that goes directly to the hotel link for Annie Appleseed Project meeting.
Tuesday, November 30, 2010
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review (abstract) Dr Yi Pan (author)
(case report/review) Conclusions Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.
Friday, November 26, 2010
Thursday, November 18, 2010
Prof Timothy Perren - Leeds Teaching Hospitals NHS Trust, UK, The ICON7 trial on ecancer tv (Avastin)
Wednesday, November 17, 2010
".....The team, testing 203 samples with OncoMap, found mutations of 50 genes in total. Some mutations were in genes previously identified in ovarian cancer, including KRAS, CTNNB1, and PIK3CA. Others were not previously known to occur in this disease, but, importantly, are potential drug targets with existing agents. "It’s not like HER2 in breast cancer where that is found in about 30% of breast cancers – we found many mutations in the ovarian cancer samples and they were infrequent," Dr. Matulonis said in a telephone interview prior to the conference; she noted, however, that OncoMap identified KRAS and PIK3CA mutations as the most common, occurring in about 25% of tumors, and "that was reassuring," as it was in line with expectations..........Dr. Matulonis’ team is now using OncoMap on all new ovarian cancers, including nonserous cancers, diagnosed at Dana-Farber, and she predicted the test will become standard in clinical practice within 6 months to a year..........cont'd
(Halifax, NS) Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer - MarketWatch
PARP (1 and 2) inhibitor, MK-4827, shows anti-tumor activity in first trial in humans (mutation/non mutation carriers)
"He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."
science article: Duke continues investigation as geneticist's work retracted (ovarian cancer patients to cisplatin drug therapy)
A prIME Oncology educational activity held after the official ESMO program hours: Evolving Strategies in the Management of Advanced Ovarian Cancer Oct
Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD
Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS
Beyond antiangiogenesis: What are the options?
Andres Poveda, MD
This Webcast contains video and downloadable slides from our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer,” a prIME Oncology educational activity that was held after the official ESMO program hours on Monday, 11 October in Milan, Italy.
Tuesday, November 16, 2010
Nov 16th: Wide Genetic Testing for Lynch Syndrome Cost Effective « AACR News telephone conference Nov 18th ET U.S./Canada
The American Association for Cancer Research will host a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET. Reporters and other interested parties can participate by using the following information:
- Dial-in (U.S. and Canada): (888) 282-7404
- Dial-in (International): (706) 679-5207
- Access Code: 20084557
Updated Oct 2010: Genetic Syndromes - Genetics of Breast and Ovarian Cancer - National Cancer Institute
Penetrance of Mutations
Cancer risk in individuals who test negative for a known familial BRCA1/2 mutation
Breast and ovarian cancer risk in breast cancer families without detectable BRCA1/2 mutations
An archived video of the full meeting is available through the NIH Videocast Web site.
"...Li-Fraumeni syndrome was first described in a 1969 publication in the Annals of Internal Medicine by Dr. Joseph F. Fraumeni, Jr., the director of DCEG, and his colleague Dr. Frederick P. Li. They described four families in which several members developed a wide variety of cancers as children or young adults. Many of the patients had multiple primary tumors, most notably breast cancer, soft tissue and bone sarcomas, brain tumors, adrenocortical neoplasms, and acute leukemia. Subsequent studies identified additional families that met the classic criteria for LFS. Other families had similar but less pronounced aggregations of cancer and were classified as Li-Fraumeni-like (LFL)...."
Expansion of cancer care and control in countries of low and middle income: a call to action : The Lancet
Note: includes a number of easy to read charts/comparisons
abstract + Free Full-Text (2010) Familial Pancreatic Cancer (includes discussion regarding BRCA/Lynch Syndrome/FAMMM and others)
Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer